5117W-11A Phase II Clinical Trial Evaluating DCVax®-Brain, Autologous Dendritic Cells Pulsed w...

A Phase II Clinical Trial Evaluating DCVax®-Brain, Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen for the Treatment of Glioblastoma Multiforme

Type of Study
Neuroscience - Brain Tumor
Short Description

The primary objective of this study is to evaluate progression-free-survival in patients receiving DCVax-Brain to treat GBM.

Status
Open
Principal Investigator
Greg Foltz, MD
Eligibility Notes

Inclusion:

  • 18 to 70 years
  • Life expectancy greater than 8 weeks

Exclusion:

  • History of malignancy
  • History of immuodeficiency or autoimmune disease
Contact Name
Nathan Hansen
Phone
206-320-3542
Email
nathan.hansen@swedish.org